Thursday, September 24Thursday, 24 September 2026 - EST (Eastern Time, UTC-05:00

Please contact Jennifer Wickett for more information: Jennifer.Wickett@informa.com

• RNA-based therapeutics and other advanced modalities are often limited by rapid hepatic uptake and clearance, reducing systemic bioavailability, restricting delivery beyond the liver, and contributing to liver-associated toxicity. These delivery barriers can constrain dose, efficacy, and therapeutic window.
• Nanobiotix’s Nanoprimer is a biocompatible, engineered liposome platform designed to transiently occupy cells of the mononuclear phagocyte system involved in hepatic clearance. Administered shortly before the therapeutic agent, Nanoprimer is designed to reduce liver elimination during the agent’s critical window of activity, increasing systemic exposure and improving the opportunity for target-tissue delivery.
• Multiple preclinical proof-of-concept studies have been demonstrated across modalities, including nucleic acid-LNPs, liposomes, oncolytic viruses, and recombinant proteins. By decreasing liver clearance, Nanoprimer has shown the potential to enhance efficacy, improve extrahepatic exposure, and reduce hepatotoxicity for therapies whose performance is limited by rapid hepatic uptake.

Please contact Jennifer Wickett for more information: Jennifer.Wickett@informa.com

An open Q&A session offering attendees the opportunity to engage directly with leading investors, gain insights into funding strategies, market trends, and what drives investment decisions in the RNA therapeutics space.

An open Q&A session providing attendees the chance to interact with pharma leaders, explore industry perspectives, and discuss strategies for advancing RNA therapeutics from discovery to commercialization.